SavedAdd your journal

Journals / The European Research Journal / 2026 / Volume: 9 Issue: 5

Effect of celecoxib on intra-abdominal sepsis-induced lung injury in rats

Cengiz Dıbekoglu(Department of General Surgery, Demiroğlu Bilim University, Faculty of Medicine, Istanbul, Turkey)0000-0001-7124-4385
Ejder Saylav Bora(Department of Emergency Medicine, İzmir Atatürk Training and Research Hospital, İzmir, Turkey)0000-0002-2448-2337
Ebru Eroğlu(Department of Histology and Embryology, Ege University, Faculty of Medicine, Izmir, Turkey)0000-0002-8087-4159
Guner Yurtsever(Department of Emergency Medicine, İzmir Atatürk Training and Research Hospital, İzmir, Turkey)0000-0002-6803-1239
Yiğit Uyanıkgil(Department of Histology and Embryology, Ege University, Faculty of Medicine, Izmir, Turkey)0000-0002-4016-0522
Oytun Erbaş(Department of Physiology, Demiroğlu Bilim University, Faculty of Medicine, Istanbul, Turkey)0000-0002-2515-2946
Pages
—
Publication Date
2023-09-04
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Celecoxib demonstrated preventive effects against sepsis-induced lung injury in rats by mitigating oxidative stress and inflammation, thereby preserving lung tissue integrity—further research, including clinical trials, to validate its effectiveness and safety in human sepsis management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This experimental study investigated the preventive effects of Celecoxib, a selective COX-2 inhibitor, on lung injury induced by intra-abdominal sepsis in rats.
📊
Key Findings & Data:Sepsis was induced using fecal intraperitoneal injection (FIP), followed by a one-hour administration of Celecoxib at 50 mg/kg/day to the treatment group.
💡
Conclusion & Impact:Conclusions: Celecoxib demonstrated preventive effects against sepsis-induced lung injury in rats by mitigating oxidative stress and inflammation, thereby preserving lung tissue integrity—further research, including clinical trials, to validate its effectiveness and safety in human sepsis management.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Celecoxib · lung injury · sepsis

Abstract

Objectives: This experimental study investigated the preventive effects of Celecoxib, a selective COX-2 inhibitor, on lung injury induced by intra-abdominal sepsis in rats. The study assessed Celecoxib's potential to mitigate the harmful impacts of sepsis on lung tissue. Methods: Thirty male Wistar albino rats, divided into three groups: a normal control group, a sepsis-induced group treated with saline, and a sepsis-induced group treated with Celecoxib. Sepsis was induced using fecal intraperitoneal injection (FIP), followed by a one-hour administration of Celecoxib at 50 mg/kg/day to the treatment group. Biochemical analysis of lung tissue measured oxidative stress markers (malondialdehyde [MDA]) and pro-inflammatory cytokines (Tumor Necrosis Faftor-α [TNF-α]). Histopathological examination evaluated lung tissue damage, encompassing alveolar congestion, hemorrhage, inflammatory cell aggregation, and edema. Arterial blood gas analysis quantified partial oxygen (PaO2) and carbon dioxide (PaCO2) pressures. Results: Celecoxib-treated rats exhibited reduced oxidative stress markers with lower MDA levels, indicating decreased oxidative damage in lung tissue. Moreover, TNF-α and other pro-inflammatory cytokines were significantly reduced in lung tissues of Celecoxib-treated rats, indicating its anti-inflammatory effects. Histopathological examination revealed reduced lung tissue damage in Celecoxib-treated rats, including alveolar congestion, hemorrhage, and inflammatory cell aggregation. Arterial blood gas analysis showed improved oxygenation (PaO2) in the Celecoxib-treated group compared to untreated sepsis rats. Conclusions: Celecoxib demonstrated preventive effects against sepsis-induced lung injury in rats by mitigating oxidative stress and inflammation, thereby preserving lung tissue integrity—further research, including clinical trials, to validate its effectiveness and safety in human sepsis management.

🔖

Cite This Article

Dıbekoglu, C., Bora, E. S., Eroğlu, E., Yurtsever, G., Uyanıkgil, Y., Erbaş, O. (2023). Effect of celecoxib on intra-abdominal sepsis-induced lung injury in rats. The European Research Journal, Volume: 9 Issue: 5. https://doi.org/10.18621/eurj.1333071

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801-10.
  2. Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019;321:2003-17.
  3. Gavelli F, Castello LM, Avanzi GC. Management of sepsis and septic shock in the emergency department. Intern Emerg Med 2021;16:1649-61.
  4. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med 2011;32:569-80.
  5. Villa-Hermosilla MC, Negro S, Barcia E, Hurtado C, Montejo C, Alonso M, et al. Celecoxib microparticles for inhalation in COVID-19-related acute respiratory distress syndrome. Pharmaceutics 2022;14:1392.
  6. Senousy SR, El-Daly M, Ibrahim ARN, Khalifa MMA, Ahmed AF. Effect of celecoxib and infliximab against multiple organ damage induced by sepsis in rats: a comparative study. Biomedicines 2022;10:1613.
  7. Scott J, Ruchaud-Sparagano MH, Musgrave K, Roy AI, Wright SE, Perry JD, et al. Phosphoinositide 3-kinase δ inhibition improves neutrophil bacterial killing in critically Ill patients at high risk of infection. J Immunol 2021;207:1776-84.
  8. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42.
  9. Wood AJ, Vassallo AM, Ruchaud-Sparagano MH, Scott J, Zinnato C, Gonzalez-Tejedo C, et al. C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling. JCI Insight 2020;5:e137029.
  10. Shaw TD, McAuley DF, O’Kane CM Emerging drugs for treating the acute respiratory distress syndrome. Expert Opin Emerg Drugs 2019;24:29-41.
  11. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 2010;23:243-52.
  12. Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res 2019;6:e000420.
  13. Alsaegh H, Eweis H, Kamal F, Alrafiah A. Celecoxib decrease seizures susceptibility in a rat model of inflammation by inhibiting HMGB1 translocation. Pharmaceuticals (Basel) 2021;14:380.
  14. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev 2017;5:CD009865
  15. Karaali R, Saylav Bora E, Acar H, Uyanikgil Y, Sever IH, Erdogan MA, et al. Exploring beta blockers’ efficacy in sepsis-induced acute lung injury and HMGB1-sRAGE interaction. Int J Pharmacol 2023;19: 296-304.
  16. Kwon WY, Suh GJ, Kim KS, Kwak YH. Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-[kappa]B pathway. Crit Care Med 2011;39:328-34.
  17. Liu D, Wang Y, Li L, Zhao H, Li L, Liu Y, et al. Celecoxib protects hyperoxia-induced lung injury via NF-κB and AQP1. Front Pediatr 2019;7:228.
  18. Mazhari S, Razi M, Sadrkhanlou R. Silymarin and Celecoxib ameliorate experimental varicocele-induced pathogenesis: evidence for oxidative stress and inflammation inhibition. Int Urol nephrol 2018;50:1039-52.
  19. Gurusamy M, Nasseri S, Rampa DR, Feng H, Lee D, Pekcec A, et al. Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice. J Transl Med 2021;19:340.
  20. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
  21. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2012;9(2 Suppl):28-35.
  22. Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, et al. Induction of claudin-4 by non-steroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res 2005;65:1868-76.
  23. Short SS, Wang J, Castle SL, Fernandez GE, Smiley N, Zobel M, et al. Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis. Lab Invest 2013;93:1265-75.